According to the ETF Finder at ETF Channel, NKTR makes up 4.01% of the First Trust NYSE Arca Biotechnology Index Fund ETF (FBT) which is relatively unchanged on the day Friday.
In afternoon trading Friday, NKTR was down about 1.5% on the day.
A series of clinical trials will test the combination of Bristol-Myers Squibb's Opdivo with Nektar's NKTR-214 in multiple tumor types.
Backed by the government, initiatives to develop and popularize non-opioid painkillers can make investors high on profits.
The big issue is if the market can build on Friday's jobs good news.